Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Want to see CRDF full AI Analyst Report?
Top Page
Cardiff Oncology
(NASDAQ:CRDF)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▼(-16.67% Downside)
Action:Reiterated
Date:05/20/26
The score is held down primarily by weak financial performance (minimal revenue, large losses, and persistent cash burn), only partially offset by low leverage. Technicals are broadly neutral with a weaker longer-term trend, while valuation is constrained by negative earnings and no dividend. Corporate events add some upside from clinical progress and leadership strengthening, but the IP-related lawsuit increases risk.
Positive Factors
Low financial leverage
Cardiff's balance sheet shows very low nominal debt and a ~0.02x debt/equity ratio, providing durable financial flexibility. For a cash-burning biotech, low leverage reduces near-term refinancing strain and interest burden, preserving optionality to raise capital on manageable terms.
Negative Factors
Persistent negative cash flow
Cardiff consistently burns cash at material levels (~-$37M TTM operating and free cash flow), creating a structural funding need. Over 2–6 months this compels external financing, raising dilution and execution risk and constraining the company's ability to expand trials or commercial preparedness without new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Cardiff's balance sheet shows very low nominal debt and a ~0.02x debt/equity ratio, providing durable financial flexibility. For a cash-burning biotech, low leverage reduces near-term refinancing strain and interest burden, preserving optionality to raise capital on manageable terms.
Read all positive factors
Cardiff Oncology (CRDF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$121.70M
Dividend YieldN/A
Average Volume (3M)851.25K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth-10.71%
EPS Growth28.59%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding68,369,896
10 Day Avg. Volume1,130,662
30 Day Avg. Volume851,248
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue216.76
Enterprise Value/Gross Profit-10.09
Enterprise Value/Ebitda-2.49
Forecast
1Y Price Target
$9.33Price Target Upside418.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$281.56K
Cardiff Oncology Business Overview & Revenue Model
Company Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, a...
How the Company Makes Money
As a clinical-stage oncology drug developer, Cardiff Oncology does not have recurring product revenue from marketed therapies (null for commercial drug sales revenue). The company funds operations primarily through external financing, which typica...
Cardiff Oncology Earnings Call Summary
Earnings Call Date:Feb 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong initial clinical data, successful capital raising efforts, and a solid financial position. However, some dependency on future FDA meetings and the early stage of PFS data might pose challenges. Overall, the sentiment is optimistic with clear progress, yet some uncertainties remain.Positive Updates
Encouraging Initial Data from CRDF-004 Trial
The trial showed a 64% ORR for patients on the 30 mg dose of onvansertib, compared to a 33% ORR in the control arm, indicating a strong efficacy signal.
Negative Updates
Pending FDA Discussions
While progress has been made, key decisions regarding dose selection and trial design depend on future FDA meetings, which could impact timelines.
Read all updates
Q4-2024 Updates
Positive
Negative
Encouraging Initial Data from CRDF-004 Trial
The trial showed a 64% ORR for patients on the 30 mg dose of onvansertib, compared to a 33% ORR in the control arm, indicating a strong efficacy signal.
Read all positive updates
Company Guidance
During the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call, guidance was provided on several key metrics and future plans for the company. The company highlighted an initial data set from the CRDF-004 trial, which showed a 64% overall response rate (ORR) for patients on the 30 mg dose of onvansertib, compared to 33% in the control arm. The trial focuses on first-line RAS-mutated metastatic colorectal cancer (mCRC), and aims to complete enrollment of 90 evaluable patients in early 2025. The company plans to release additional clinical data in the first half of 2025. Financially, Cardiff Oncology reported $91.7 million in cash and short-term investments as of December 31, 2024, following a $40 million capital raise. The company projects that these resources will support operations into the first quarter of 2027, with a quarterly cash burn of $10.3 million in Q4 2024. Additionally, Cardiff Oncology strengthened its intellectual property portfolio with a new patent for onvansertib, expected to expire no earlier than 2043.Cardiff Oncology Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 525.00K | 593.00K | 683.00K | 488.00K | 386.00K | 359.00K |
| Gross Profit | -11.28M | 593.00K | 683.00K | 488.00K | 386.00K | 359.00K |
| EBITDA | -45.68M | -48.06M | -48.25M | -45.01M | -39.67M | -28.40M |
| Net Income | -44.77M | -45.85M | -45.43M | -41.44M | -38.70M | -28.29M |
Balance Sheet | ||||||
| Total Assets | 49.17M | 61.88M | 97.19M | 81.64M | 116.19M | 149.54M |
| Cash, Cash Equivalents and Short-Term Investments | 46.06M | 58.30M | 91.75M | 74.82M | 105.27M | 140.82M |
| Total Debt | 646.00K | 832.00K | 1.52M | 2.15M | 2.71M | 3.12M |
| Total Liabilities | 14.46M | 16.50M | 14.24M | 11.90M | 9.85M | 9.13M |
| Stockholders Equity | 34.71M | 45.39M | 82.95M | 69.74M | 106.34M | 140.42M |
Cash Flow | ||||||
| Free Cash Flow | -37.46M | -37.97M | -37.77M | -31.47M | -34.71M | -23.25M |
| Operating Cash Flow | -37.42M | -37.92M | -37.69M | -30.89M | -33.82M | -23.04M |
| Investing Cash Flow | 19.18M | 1.34M | 13.73M | 36.20M | 38.15M | -131.45M |
| Financing Cash Flow | 2.68M | 2.58M | 53.78M | 0.00 | 75.00K | 35.45M |
Cardiff Oncology Technical Analysis
Positive
1.80
Price Trends
1.69
Positive
1.93
Negative
2.09
Negative
Market Momentum
0.02
Negative
55.73
Neutral
51.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRDF, the sentiment is Positive. The current price of 1.8 is above the 20-day moving average (MA) of 1.69, above the 50-day MA of 1.69, and below the 200-day MA of 2.09, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.73 is Neutral, neither overbought nor oversold. The STOCH value of 51.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRDF.
Cardiff Oncology Risk Analysis
Cardiff Oncology disclosed 56 risk factors in its most recent earnings report. Cardiff Oncology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cardiff Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $859.45M | -3.82 | -97.55% | ― | -86.62% | -1121.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $124.18M | -1.00 | -135.60% | ― | ― | 17.43% | |
47 Neutral | $121.70M | -2.24 | -95.51% | ― | -10.71% | 28.59% | |
45 Neutral | $96.62M | -3.59 | 4596.70% | ― | ― | 13.21% | |
44 Neutral | $162.10M | -1.77 | -49.86% | ― | -100.00% | 0.03% |
* Healthcare Sector Average
CRDF
Cardiff Oncology
1.78
-1.25
-41.25%
ONCY
Oncolytics Biotech
0.81
0.39
93.54%
AVTX
Avalo Therapeutics
16.35
12.60
336.00%
GLSI
Greenwich LifeSciences
27.65
17.67
177.05%
MOLN
Molecular Partners
4.18
0.12
2.96%
PYXS
Pyxis Oncology
1.96
0.72
58.06%
Cardiff Oncology Corporate Events
Business Operations and StrategyLegal Proceedings
Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights
Negative
May 19, 2026
On May 19, 2026, Cardiff Oncology, Inc. filed a lawsuit in the U.S. District Court for the Southern District of California against Nerviano Medical Sciences S.r.L., challenging allegations that it materially breached their license agreement for th...
Business Operations and StrategyExecutive/Board Changes
Cardiff Oncology appoints new CEO, CFO and COO
Positive
Apr 9, 2026
On April 9, 2026, Cardiff Oncology announced that interim CEO and board member Mani Mohindru, PhD, has been appointed President and Chief Executive Officer, while industry veterans Josh Muntner and Ajay Aggarwal, MD, MBA, were named Chief Financia...
Business Operations and StrategyExecutive/Board Changes
Cardiff Oncology Formalizes Executive Departures Amid Strategic Review
Neutral
Apr 2, 2026
Cardiff Oncology disclosed that on January 26, 2026 its CEO, Dr. Mark Erlander, and CFO, James Levine, stepped down as part of a strategic review, and on March 27, 2026 the company formalized their departures with separation agreements. Erlander w...
Business Operations and StrategyProduct-Related Announcements
Cardiff Oncology advances onvansertib program in colorectal cancer
Positive
Feb 25, 2026
Cardiff Oncology has outlined new clinical data and development plans for its PLK1 inhibitor onvansertib, highlighting strong efficacy signals in first-line RAS-mutant metastatic colorectal cancer, including a 72% confirmed overall response rate a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.